Porcine collagen compositions and methods of use thereof
AssigneeOrganogenesis, Inc.
InventorsPatrick Bilbo, Katherine Faria, Bonnie Kathleen Mowry, Vivek Raut
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods related to wound management. The compositions include a micronized extracellular matrix and in some instances one or more antimicrobial agents. In some embodiments, the extracellular matrix is comprised of a porcine purified collagen wound matrix (CWM) and polyhexamethylene biguanide (PHMB). The composition is formulated as a powder and may be applied to a wound as a powder, or hydrated and applied to a wounds as a paste or a slurry.
Claims23
A sterilized micronized collagen composition for use in wound management, the composition comprising micronized particles of a Collagen Wound Matrix (CWM) having a micronized average particle size of 100 to 1000 micrometers (um) in diameter, wherein the composition comprises greater than 95% (w/w) native porcine Type I collagen, wherein the micronized particles are flakes, wherein the composition is for application to a wound, wherein the wound is an irregularly shaped wound or a tunneling wound, and wherein the micronized size of the composition allows direct contact to the entirety of the bed of the wound.
A method for managing a wound in a subject in need thereof comprising
- cleaning the wound of debris and necrotic tissue;
- and
- applying a sterilized micronized collagen composition to the entire area of the wound, wherein the composition comprises micronized particles of a Collagen Wound Matrix (CWM) having a micronized average particle size of 1000 micrometers (um) or less in diameter, wherein the composition comprises greater than 95% (w/w) native porcine Type I collagen, wherein the micronized particles are flakes, wherein the wound is an irregularly shaped wound or a tunneling wound, and wherein the micronized size of the composition allows direct contact to the entirety of the bed of the wound.
A sterilized micronized collagen composition for use in the manufacture of a medicament for wound management, the composition comprising micronized particles of a Collagen Wound Matrix (CWM) having a micronized average particle size of 100 to 1000 micrometers (μm) in diameter, wherein the composition comprises greater than 95% (w/w) native porcine Type I collagen, less than 0.7% (w/w) lipids, less than 1.0% (w/w) glycosaminoglycans, and less than 0.1 nanograms per milliliter (ng/ml) DNA, wherein the native porcine Type I collagen is free of cells and cell remnants, wherein the micronized particles are flakes, wherein the composition is for application to a wound, wherein the wound is an irregularly shaped wound or a tunneling wound selected from the group consisting of a partial thickness wound, a full-thickness wound, a pressure ulcer, a venous ulcer, a diabetic ulcer, a chronic vascular ulcer, a tunneled wound, an undermined wound, a surgical wound, wound dehiscence, a trauma wound, a second degree burn, and a draining wound, and wherein the micronized size of the composition allows direct contact to the entirety of the bed of the wound.
A sterilized and packaged micronized collagen powder device for use in wound management, the device comprising micronized particles of a Collagen Wound Matrix (CWM) having a micronized average particle size of 100 to 1000 micrometers (μm) in diameter, wherein the device comprises greater than 95% (w/w) native porcine Type I collagen, wherein the micronized particles are flakes, wherein the device is for application to a wound, wherein the wound is an irregularly shaped wound or a tunneling wound, wherein the micronized size of the device allows direct contact to the entirety of the bed of the wound, and wherein the device is situated within one or more packages.
Dependencies are inferred from the claim text.